Clinical Trial

Treatment of Advanced Solid and Hematologic Cancers

Study Description

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers

Study CC-95251-ST-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Parts B and C), first-in-human clinical study of CC-95251 in subjects with advanced cancers.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - CC-95251

CC-95251 administered by IV (intravenous) infusion.

Drug - Rituximab

Rituximab administered by IV (intravenous) infusion.

Drug - Cetuximab

Cetuximab administered by IV (intravenous) infusion.

Additional Information

Official Study Title

A Phase 1, Open-Label, Dose Finding Study of CC-95251, A Monoclonal Antibody Directed Against SIRPa, Alone and in Combination With Cetuximab or Rituximab in Subjects With Advanced Solid and Hematologic Cancers

Clinical Trial ID

NCT03783403

ParticipAid ID

aM8oQe